The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

The FDA and EMA's joint guidance was created to ensure the pharmaceutical industry employs best practices when using AI in ...

Early-stage regulatory strategy is becoming a powerful driver of speed, risk reduction, and commercial value in drug ...

The U.S. Food and Drug Administration and the European Medicines Agency jointly issued principles for safe and responsible ...

In today’s ACT Brief, we look at how AI is reshaping clinical trial registries into discovery tools, why contract and budget negotiations remain the biggest drag on site activation timelines, and how ...

The FDA’s new draft guidance on Bayesian methodology signals a shift toward more flexible, data-driven clinical trial designs, enabling sponsors to use prior data and adaptive approaches to improve ...

FDA proposes framework clinical trial designs to guide Bayesian methods, improving efficiency in drug development for rare and pediatric conditions.

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

The world of medicine has taken a significant leap forward with the first AI-generated drug entering clinical trials. This breakthrough has the potential to revolutionize drug discovery, transforming ...

AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use ...

After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...